Last 12 months
Inside the activity.
0 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2020 Filed Sep 23, 2020 13:20 UTC |
Davis BlaineChief Financial Officer
|
PurchaseCommon Stock | 1,481 | $16.91 | $25,037.79 |
DisclosureSEC source: 0001209191-20-051631 · doc4.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481 F1 · price: The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.885 to $16.935, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 18:04 UTC |
Marshall RandallFormer 10% Owner
|
SaleCommon Stock | 474 | $20.00 | $9,480.00 |
DisclosureSEC source: 0001179110-20-009785 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,600 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 18:04 UTC |
Marshall RandallFormer 10% Owner
|
SaleCommon Stock | 2,080 | $19.26 | $40,060.80 |
DisclosureSEC source: 0001179110-20-009785 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,074 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.50, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 16:37 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 239 | $18.00 | $4,302.00 |
DisclosureSEC source: 0001179110-20-009717 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,154 Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 15:58 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 4,913 | $19.27 | $94,673.51 |
DisclosureSEC source: 0001179110-20-009662 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,393 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.02 to $19.715, inclusive. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 15:58 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 5,309 | $18.10 | $96,092.90 |
DisclosureSEC source: 0001179110-20-009662 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,306 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.82, inclusive. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 15:58 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 3,108 | $18.94 | $58,865.52 |
DisclosureSEC source: 0001179110-20-009662 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,615 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.29, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 16:39 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 52 | $20.19 | $1,049.88 |
DisclosureSEC source: 0001179110-20-009590 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,723 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.20, inclusive. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 16:39 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 207 | $20.68 | $4,280.76 |
DisclosureSEC source: 0001179110-20-009590 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,775 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.21 to $20.80, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 16:53 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 771 | $22.09 | $17,031.39 |
DisclosureSEC source: 0001179110-20-009466 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,982 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.475, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 15:56 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 616 | $22.37 | $13,779.92 |
DisclosureSEC source: 0001179110-20-009407 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,753 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.08 to $23.005, inclusive. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 15:56 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,418 | $22.40 | $31,763.20 |
DisclosureSEC source: 0001179110-20-009407 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,369 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.15 to $23.03, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 16:27 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 2,461 | $22.73 | $55,938.53 |
DisclosureSEC source: 0001179110-20-009359 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,787 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.16 to $23.10, inclusive. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:27 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 974 | $23.16 | $22,557.84 |
DisclosureSEC source: 0001179110-20-009359 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,248 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.09 to $23.29, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 09:51 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 510 | $24.18 | $12,333.33 |
DisclosureSEC source: 0001179110-20-009241 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,222 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.515, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to this Form 4. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:18 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 200 | $25.19 | $5,038.00 |
DisclosureSEC source: 0001179110-20-009191 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,732 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.11 to $25.28, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to this Form 4. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 17:48 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,548 | $25.11 | $38,870.28 |
DisclosureSEC source: 0001179110-20-009153 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,932 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.55, inclusive. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 17:48 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 700 | $25.09 | $17,563.00 |
DisclosureSEC source: 0001179110-20-009153 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,480 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.32, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 16:59 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,317 | $26.14 | $34,426.38 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 4 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,180 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.525, inclusive. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:59 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 100 | $28.45 | $2,845.00 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,497 Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:59 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 600 | $27.28 | $16,368.00 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,597 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.83, inclusive. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:59 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,816 | $26.03 | $47,270.48 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,197 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.35, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 600 | $35.45 | $21,270.00 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 8 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,013 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.00, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,650 | $33.79 | $55,753.50 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 7 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,613 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.34, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,200 | $33.09 | $39,708.00 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 6 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,263 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.60 to $33.34, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 3,493 | $31.53 | $110,134.29 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 5 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,463 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $32.01, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 14,243 | $30.42 | $433,272.06 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 4 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 621,956 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $31.00, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,811 | $28.63 | $51,848.93 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,199 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.41, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 2,600 | $26.85 | $69,810.00 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,010 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.38 to $27.38, inclusive. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 338 | $26.08 | $8,815.04 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,610 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.06 to $26.24, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to (8) to this Form 4. Read SEC document |
| July 24, 2020 Filed Jul 27, 2020 16:07 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 300 | $26.00 | $7,800.00 |
DisclosureSEC source: 0001179110-20-008490 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,948 Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:07 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 93 | $27.29 | $2,537.97 |
DisclosureSEC source: 0001179110-20-008490 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,248 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 to $27.49, inclusive. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:07 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,950 | $26.58 | $51,831.00 |
DisclosureSEC source: 0001179110-20-008490 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.10, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 20:45 UTC |
Flannelly Barry PDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001209191-20-043742 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,250 shares Expires 2030-07-22 F2 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 20:45 UTC |
Flannelly Barry PDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001209191-20-043742 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-07-22 F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 16:31 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 75 | $27.45 | $2,058.38 |
DisclosureSEC source: 0001179110-20-008426 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,291 Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 16:31 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,297 | $26.69 | $34,616.93 |
DisclosureSEC source: 0001179110-20-008426 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,366 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.20, inclusive. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:31 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 223 | $26.56 | $5,922.88 |
DisclosureSEC source: 0001179110-20-008426 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,663 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 and $27.05, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 16:44 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 472 | $27.68 | $13,064.96 |
DisclosureSEC source: 0001179110-20-008399 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,886 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $28.11, inclusive. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 16:44 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 2,257 | $26.70 | $60,261.90 |
DisclosureSEC source: 0001179110-20-008399 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,358 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.375 to $27.10, inclusive. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 16:44 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 1,601 | $26.66 | $42,682.66 |
DisclosureSEC source: 0001179110-20-008399 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,615 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.87, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 2,145 | $27.13 | $58,193.85 |
DisclosureSEC source: 0001179110-20-008254 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,216 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.70, inclusive. Read SEC document |
| July 10, 2020 Filed Jul 13, 2020 18:56 UTC |
Shefferman JesseDirector · CEO and President
|
GrantStock Option (Right to Buy) · Derivative | 111,250 | $0.00 Strike: $27.42 | $0.00 |
DisclosureSEC source: 0001209191-20-042242 · doc4.xml · derivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,250 Underlying: Common Stock · 111,250 shares Expires 2030-07-09 F1 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 10, 2020 and 1/48th of the shares vesting monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 16:40 UTC |
Marshall Randall10% owner
|
SaleCommon Stock | 2,659 | $27.41 | $72,883.19 |
DisclosureSEC source: 0001179110-20-008254 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,361 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.01, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:41 UTC |
Solomon Michael EdwardDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035850 · doc4.xml · derivative · entry 1 Solomon Michael Edward · CIK 0001799320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:33 UTC |
Braunstein ScottDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035846 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:43 UTC |
Levy Richard SDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035852 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:38 UTC |
GARCEAU ROGERDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035848 · doc4.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:42 UTC |
SARGEN GREGORYDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035851 · doc4.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:31 UTC |
BESHAR LUKE MDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035843 · doc4.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.